JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.52 22.58

Buy Sell

Overview

Share price change

24h

Current

Min

1.51

Max

1.58

Key metrics
By Trading Economics
Income	-124K -32M
Sales	-372K 1.4M
EPS	-0.27
Profit margin	-2,364.792
Employees	161
EBITDA	-13M -42M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+30.72% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-22M 152M
Previous open	-21.06
Previous close	1.52

News Sentiment

By Acuity

100%

330 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 maj 2026, 21:36 UTC

Acquisitions, Mergers, Takeovers

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1 maj 2026, 20:40 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1 maj 2026, 18:37 UTC

Major Market Movers

Senseonic Shares Slide on Underwritten Offering Price

1 maj 2026, 16:46 UTC

Major Market Movers

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2 maj 2026, 19:57 UTC

Acquisitions, Mergers, Takeovers

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2 maj 2026, 15:24 UTC

Earnings

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2 maj 2026, 12:46 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2 maj 2026, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

1 maj 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

1 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 maj 2026, 20:42 UTC

Earnings

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1 maj 2026, 19:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 maj 2026, 19:33 UTC

Market Talk

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1 maj 2026, 19:18 UTC

Market Talk

Major News Events

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1 maj 2026, 19:13 UTC

Market Talk

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1 maj 2026, 18:36 UTC

Earnings

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1 maj 2026, 18:35 UTC

Earnings

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 maj 2026, 18:28 UTC

Earnings

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1 maj 2026, 18:27 UTC

Market Talk

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1 maj 2026, 18:14 UTC

Acquisitions, Mergers, Takeovers

Barclays Completes Acquisition of Best Egg

1 maj 2026, 18:04 UTC

Earnings

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1 maj 2026, 17:43 UTC

Market Talk

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1 maj 2026, 17:37 UTC

Market Talk

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1 maj 2026, 17:30 UTC

Market Talk

Earnings

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1 maj 2026, 17:28 UTC

Market Talk

Earnings

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1 maj 2026, 17:21 UTC

Market Talk

Earnings

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1 maj 2026, 17:19 UTC

Market Talk

Major News Events

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1 maj 2026, 16:38 UTC

Market Talk

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1 maj 2026, 16:23 UTC

Acquisitions, Mergers, Takeovers

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1 maj 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

30.72% upside

12 Months Forecast

Average 2 USD 30.72%

High 2 USD

Low 2 USD

Based on 3 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

330 / 347 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.